Project Details
Description
PROJECT NARRATIVE
We have previously identified FDA-approved Bazedoxifene as an inhibitor of the IL-6 signaling
axis, a major oncogenic promoter of pancreatic cancer. Here we aim to investigate the feasibility
of repurposing this well-tolerated medication as a chemopreventive therapy for patients who are
at high-risk for pancreatic cancer in preclinical models. The success of our application can be
immediately translated to benefit patients who can be identified as high-risk but are not
sufficiently managed by current care (i.e. patients with detectable premalignant lesions, chronic
pancreatitis, familial mutations).
Status | Finished |
---|---|
Effective start/end date | 12/14/21 → 11/30/22 |
Funding
- National Cancer Institute: US$238,542.00
ASJC Scopus Subject Areas
- Cancer Research
- Oncology
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.